Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Prothena Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Prothena Corp Plc, Medical Devices Deals, 2012 to YTD 2018 10
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Prothena Biosciences Enters into R&D Agreement with Celgene Switzerland 12
MJFF Enters into Agreement with Prothena 14
Licensing Agreements 15
Roche Enters Into Licensing Agreement With Prothena 15
Equity Offering 17
Prothena Files Registration Statement for Public Offering of Shares 17
Prothena Raises USD155.3 Million in Public Offering of Shares 18
Prothena Raises USD137 Million in Public Offering of Shares 20
Prothena Raises USD122 Million in Public Offering of Shares 22
Prothena Completes Exercise of Underwriter’s Over Allotment Option for Public Offering of Shares for USD123 Million 24
Prothena Raises USD82.7 Million in Public Offering of Shares 26
Prothena Completes Public Offering Of Shares For US$92 Million 28
Prothena Corp Plc – Key Competitors 30
Prothena Corp Plc – Key Employees 31
Prothena Corp Plc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Strategy And Business Planning 33
May 24, 2018: Prothena Announces Reorganization to Focus Resources on Advancing Neuroscience Pipeline 33
Financial Announcements 34
Aug 07, 2018: Prothena reports second quarter 2018 financial results and provides R&D update 34
May 08, 2018: Prothena Reports First Quarter 2018 Financial Results and Provides R&D Update 36
Feb 14, 2018: Prothena Reports Fourth Quarter and Full Year 2017 Financial Results 38
Nov 07, 2017: Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update 40
Aug 08, 2017: Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update 42
May 09, 2017: Prothena Reports First Quarter 2017 Financial Results and Provides R&D Update 44
Feb 14, 2017: Prothena Reports Fourth Quarter and Full Year 2016 Financial Results, and Provides Financial Guidance and R&D Update 46
Corporate Communications 48
Jun 25, 2018: Prothena Appoints Tran B. Nguyen As Chief Operating Officer 48
Feb 02, 2018: Prothena Announces Resignation of Sarah Noonberg As Chief Medical Officer 49
Jun 12, 2017: Prothena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer 50
May 16, 2017: Prothena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer 51
Clinical Trials 52
Jun 19, 2018: Prothena Announces Phase 1b Clinical Trial Results Of PRX002/RG7935 For Parkinson’s Disease Published In JAMA Neurology 52
Jun 18, 2018: New immunotherapy could stop progression of Parkinson’s disease 53
Sep 18, 2017: Prothena Presents New Research Supporting Clinical Relevance of Cardiac Biomarker NT-proBNP in AL Amyloidosis 54
Aug 15, 2017: Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting 56
Jul 05, 2017: Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson’s Disease 57
Jun 08, 2017: Anti-Alpha-Synuclein Antibody is a Potential Disease-Modifying Treatment for Parkinson’s Disease 58
Apr 02, 2017: Clinical Results Presented from Prothena’s Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson’s Disease 59
Mar 09, 2017: Results for Prothena’s Phase 1b Multiple Ascending Dose Study of PRX002/RG7935 in Patients with Parkinson’s Disease to be Presented at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases 61
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63
Prothena Corp Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Prothena Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Prothena Corp Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Prothena Corp Plc, Medical Devices Deals, 2012 to YTD 2018 10
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Prothena Biosciences Enters into R&D Agreement with Celgene Switzerland 12
MJFF Enters into Agreement with Prothena 14
Roche Enters Into Licensing Agreement With Prothena 15
Prothena Files Registration Statement for Public Offering of Shares 17
Prothena Raises USD155.3 Million in Public Offering of Shares 18
Prothena Raises USD137 Million in Public Offering of Shares 20
Prothena Raises USD122 Million in Public Offering of Shares 22
Prothena Completes Exercise of Underwriter's Over Allotment Option for Public Offering of Shares for USD123 Million 24
Prothena Raises USD82.7 Million in Public Offering of Shares 26
Prothena Completes Public Offering Of Shares For US$92 Million 28
Prothena Corp Plc, Key Competitors 30
Prothena Corp Plc, Key Employees 31
Prothena Corp Plc, Subsidiaries 32
List of Figures
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Prothena Corp Plc, Medical Devices Deals, 2012 to YTD 2018 10